Ketamine’s promise for severe depression grows, but major questions remain

https://medicalxpress.com/news/2024-02-ketamine-severe-depression-major.html

More information: Sagar V. Parikh et al, Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression, Journal of Affective Disorders (2023). DOI: 10.1016/j.jad.2023.12.033